Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty markets through its consumer brands and as a supplier of sustainable and natural ingredients in Europe, the United States, Asia, Brazil, and internationally. It manufactures and sells products for the health and wellness, clean beauty, and flavor and fragrance markets. The company operates under the Amyris, Biofene, Biossance, Pipette, Purecane, and No Compromise trademarks. Amyris, Inc. has a collaboration agreement with the Infectious Disease Research Institute to advance a novel ribonucleic acid vaccine platform, including accelerating the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.
IPO Year: 2010
Exchange: NASDAQ
Website: amyris.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/18/2023 | $3.10 → $0.65 | Buy → Hold | Jefferies |
| 5/10/2023 | $4.00 → $1.25 | Outperform → Market Perform | TD Cowen |
| 4/28/2023 | $1.50 | Buy | Canaccord Genuity |
| 11/10/2022 | Overweight → Neutral | JP Morgan | |
| 11/9/2022 | Outperform → Perform | Oppenheimer | |
| 8/10/2022 | $4.00 → $2.00 | Buy → Neutral | ROTH Capital |
| 6/24/2022 | Neutral | JP Morgan | |
| 5/25/2022 | $2.50 | Neutral | Piper Sandler |
| 3/2/2022 | Outperform | Cowen | |
| 10/15/2021 | $19.00 | Outperform | Cowen |
Jefferies downgraded Amyris from Buy to Hold and set a new price target of $0.65 from $3.10 previously
TD Cowen downgraded Amyris from Outperform to Market Perform and set a new price target of $1.25 from $4.00 previously
Canaccord Genuity initiated coverage of Amyris with a rating of Buy and set a new price target of $1.50
JP Morgan downgraded Amyris from Overweight to Neutral
Oppenheimer downgraded Amyris from Outperform to Perform
ROTH Capital downgraded Amyris from Buy to Neutral and set a new price target of $2.00 from $4.00 previously
JP Morgan initiated coverage of Amyris with a rating of Neutral
Piper Sandler initiated coverage of Amyris with a rating of Neutral and set a new price target of $2.50
Cowen resumed coverage of Amyris with a rating of Outperform
Cowen resumed coverage of Amyris with a rating of Outperform and set a new price target of $19.00
VALENCIA, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced the appointment of Nicole Linda Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary, effective July 1, 2024. Ms. Kelsey has more than two decades of executive legal experience with expertise in M&A, securities, and governance, along with a strong track record building and leading global regulatory and compliance programs. Previously, she served as Chief Legal Officer and Secretary for Amyris, Inc. (NASDAQ:AMRS) and General Counse
EMERYVILLE, Calif., June 26, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that John Melo has resigned from his role as President & Chief Executive Officer and a member of the Board of Directors, effective immediately. The Company's Board of Directors has appointed Han Kieftenbeld as Interim Chief Executive Officer. Mr. Kieftenbeld will remain as the Company's Chief Financial Officer. The Company also announced a global reduction in force as an important step towards its previously announce
EMERYVILLE, Calif., Jan. 27, 2022 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS) ("Amyris"), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-MarketTM operating platform, today announced the appointment of Ms. Ana Dutra as its newest independent member of the Amyris Board of Directors, effective January 21, 2022. "We are very pleased to welcome Ana as a new, independent director to Amyris," said John Melo, President and Chief Executive Officer of Amyris. "Ana brings decades of leadership, operational depth and highly re
S-8 POS - AMYRIS, INC. (0001365916) (Filer)
S-8 POS - AMYRIS, INC. (0001365916) (Filer)
S-8 POS - AMYRIS, INC. (0001365916) (Filer)
S-8 POS - AMYRIS, INC. (0001365916) (Filer)
POS AM - AMYRIS, INC. (0001365916) (Filer)
POS AM - AMYRIS, INC. (0001365916) (Filer)
S-8 POS - AMYRIS, INC. (0001365916) (Filer)
S-8 POS - AMYRIS, INC. (0001365916) (Filer)
S-8 POS - AMYRIS, INC. (0001365916) (Filer)
S-8 POS - AMYRIS, INC. (0001365916) (Filer)
3 - AMYRIS, INC. (0001365916) (Issuer)
3 - AMYRIS, INC. (0001365916) (Issuer)
3 - AMYRIS, INC. (0001365916) (Issuer)
4 - AMYRIS, INC. (0001365916) (Issuer)
4 - AMYRIS, INC. (0001365916) (Issuer)
4 - AMYRIS, INC. (0001365916) (Issuer)
4 - AMYRIS, INC. (0001365916) (Issuer)
4 - AMYRIS, INC. (0001365916) (Issuer)
4 - AMYRIS, INC. (0001365916) (Issuer)
4 - AMYRIS, INC. (0001365916) (Issuer)
SC 13D/A - AMYRIS, INC. (0001365916) (Subject)
SC 13D/A - AMYRIS, INC. (0001365916) (Subject)
SC 13D/A - AMYRIS, INC. (0001365916) (Subject)
SC 13D/A - AMYRIS, INC. (0001365916) (Subject)
SC 13D/A - AMYRIS, INC. (0001365916) (Subject)
SC 13D/A - AMYRIS, INC. (0001365916) (Subject)
SC 13D/A - AMYRIS, INC. (0001365916) (Subject)
SC 13D/A - AMYRIS, INC. (0001365916) (Subject)
SC 13D/A - AMYRIS, INC. (0001365916) (Subject)
SC 13D/A - AMYRIS, INC. (0001365916) (Subject)
VALENCIA, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced the appointment of Nicole Linda Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary, effective July 1, 2024. Ms. Kelsey has more than two decades of executive legal experience with expertise in M&A, securities, and governance, along with a strong track record building and leading global regulatory and compliance programs. Previously, she served as Chief Legal Officer and Secretary for Amyris, Inc. (NASDAQ:AMRS) and General Counse
Voluntary Chapter 11 Commenced to Finalize Consensual Go-Forward Plan for Amyris' Core Business $190 Million Financing Commitment from Foris Ventures to Support Day-to-Day Operations EMERYVILLE, Calif., Aug. 9, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS) ("Amyris" or the "Company"), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it is moving forward with an operational and financial restructuring to further advance its ongoing strategic transformation and position the Company for long-term success.
EMERYVILLE, Calif., June 26, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that John Melo has resigned from his role as President & Chief Executive Officer and a member of the Board of Directors, effective immediately. The Company's Board of Directors has appointed Han Kieftenbeld as Interim Chief Executive Officer. Mr. Kieftenbeld will remain as the Company's Chief Financial Officer. The Company also announced a global reduction in force as an important step towards its previously announce
EMERYVILLE, Calif., June 5, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-MarketTM technology platform and clean beauty consumer brands, today announced that its Board of Directors has engaged the Business Recovery Services unit of PricewaterhouseCoopers ("PwC") and established a subcommittee of the Board (the "Restructuring Committee"), made up of three independent directors, working with Management, to execute on a transformation program to accelerate improvements to the Company's cost and capital structure and liquidity.
EMERYVILLE, Calif., May 19, 2023 Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it has signed an exclusive license agreement with British specialty chemicals company Croda International Plc, ("Croda") for the supply of sustainable squalene. Amyris' squalene is a biofermentation-based adjuvant developed using Amyris' unique Lab-to-Market technology platform. Squalene, used in adjuvants to boos
Core revenue of $56.1 million exceeded Q1 guidance of $49.9 millionCash operating expense down 4% compared to Q1 2022 and down 24% versus Q4 2022Completed strategic partnership with Givaudan on April 3 for $200 million upfront cashEMERYVILLE, Calif., May 9, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-MarketTM technology platform and clean beauty consumer brands, today announced financial results for the first quarter ended March 31, 2023. Q1 2023
EMERYVILLE, Calif., May 2, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it will issue its financial results for the first quarter ended March 31, 2023, on the afternoon of Tuesday, May 9, 2023, after closing of the financial markets. The company will hold a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time), during which, John Melo, President
EMERYVILLE, Calif., April 24, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, provided an update on first quarter revenue. The Company expects to deliver Q1 2023 total revenue of approximately $56 million. The Company previously guided to revenue of approximately $50 million during the fourth quarter earnings call. Gross profit and operating expense are expected to be sequentially significantl
Leveraging Amyris' industry-leading biotechnology platform in Beauty for the development and supply of clean sustainable ingredients EMERYVILLE, Calif., April 5, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, announced that it has completed the previously announced strategic transaction with Givaudan SA for the worldwide exclusive licensing of certain cosmetic ingredients, including Neossance® Squalane, the highest performant emollient, Neossance® Hemisqualane, the plant-based silicone alternative, and Clea
Fourth quarter Consumer revenue of $52.8 million increased 64% over the prior year and was another record quarter. Core revenue of $75.8 million grew 17% over the prior yearFull year Consumer revenue of $176.9 million increased 92% and outperformed prestige beauty industry growth of 15%. Core revenue of $269.8 million grew 44% over prior yearUse of cash for operating and investing activities sequentially improved each quarter; Q4 2022 down $102 million versus Q1 2022Actions taken to simplify portfolio, streamline management structure and deliver efficienciesEMERYVILLE, Calif., March 15, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating th
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. This growth would be primarily fueled by the expansion of adult-use markets and adoption of new licensed and regulated markets, both medical and recreational. Key states driving this surge include New York, New Jersey and potentially Florida and Ohio, Bingham says. Influence Of DEA Rescheduling Following the DEA's decision to reclassify cannabis to Schedule III, Bingham predicts this will open up new avenues for medical research and investment. "We expect major medical discoveries within five years," he stated, highlighting the potential for new pharm
Gainers PhenomeX Inc. (NASDAQ:CELL) shares surged 138.3% to $0.9532. Bruker Corporation and PhenomeX reported a $108 million definitive agreement for Bruker to acquire PhenomeX in an all-cash transaction for $1 per share. Tivic Health Systems, Inc. (NASDAQ:TIVC) shares jumped 39.1% to $0.0932. Tivic Health Systems shares jumped 80% on Wednesday after the company announced its funded study started enrollment for its non-invasive bioelectronic device approach to vagus nerve stimulation. Sunlight Financial Holdings Inc. (NYSE:SUNL) climbed 36.9% to $0.2101 after declining 8% on Wednesday. Advanced Health Intelligence Ltd. (NASDAQ:AHI) shares rose 30.2% to $5.00. Advanced Health Intelligen
Gainers AGBA Group Holding Limited (NASDAQ:AGBA) shares surged 49.4% to $1.31 in pre-market trading after the company reported a 325% year-over-year growth in its second-quarter revenue. AMC Entertainment Hldg Pref Equity Units (NYSE:APE) rose 29.8% to $2.31 in pre-market trading after AMC gained court approval for its revised stock conversion plan. Proterra Inc. (NASDAQ:PTRA) shares gained 25.2% to $0.1483 in pre-market trading on continued volatility after the company announced it filed for Chapter 11 bankruptcy. United States Steel Corporation (NYSE:X) shares rose 23% to $27.95 in pre-market trading. United States Steel late Sunday rejected a buyout offer from rival steel manufactu
Gainers Amyris, Inc. (NASDAQ:AMRS) shares jumped 179.1% to $0.1839. Amyris shares dipped over 80% on Thursday after the company announced it filed for Chapter 11 bankruptcy. Rigetti Computing, Inc. (NASDAQ:RGTI) shares climbed 51.2% to $2.48 following a narrower-than-expected quarterly loss. Telesat Corporation (NASDAQ:TSAT) gained 47.2% to $12.44 after the company reported second-quarter results and tapped MDA under a $2.1 billion deal as prime satellite manufacturer of advanced Telesat Lightspeed Low Earth Orbit constellation. Proterra Inc. (NASDAQ:PTRA) jumped 37% to $0.1442 on continued volatility after the company announced it filed for Chapter 11 bankruptcy. Ouster, Inc. (NYS
Amyris, Inc. (NASDAQ:AMRS) shares are trading higher Friday as the stock rebounds following a steep selloff after the company announced it filed for Chapter 11 bankruptcy. The Details: Amyris shares closed down by nearly 90% on Thursday after the company announced that it had commenced voluntary Chapter 11 proceedings in the U.S. Bankruptcy Court for the District of Delaware. Han Kieftenbeld, CFO of Amyris, stated, "We remain incredibly excited about Amyris' long-term potential and our uniquely talented team's proven ability to deliver on the promise of synthetic biology and continue to make a lasting impact. At the end of this restructuring process, we believe that Amyris will emerge as a
U.S. stocks traded mixed midway through trading, with the Dow Jones gaining around 100 points on Friday. The Dow traded up 0.30% to 35,280.26 while the NASDAQ fell 0.48% to 13,672.51. The S&P 500, also fell, dropping, 0.05% to 4,466.72. Check This Out: Amazon To Rally Over 66%? Here Are 10 Other Analyst Forecasts For Friday Leading and Lagging Sectors Energy shares jumped by 1.6% on Friday. In trading on Friday, information technology shares fell by 0.8%. Top Headline The University of Michigan consumer sentiment fell to 71.2 in August from 71.6 in the previous month, but topped market estimates of 71. Equities Trading UP Amyris, Inc. (NASDAQ:AMRS) shares shot up 141% to $0.158
U.S. stocks traded lower this morning, following the release of PPI data on Friday. Following the market opening Friday, the Dow traded down 0.16% to 35,121.51 while the NASDAQ fell 0.84% to 13,622.68. The S&P 500, also fell, dropping, 0.49% to 4,446.98. Check This Out: Amazon To Rally Over 66%? Here Are 10 Other Analyst Forecasts For Friday Leading and Lagging Sectors Energy shares jumped by 0.3% on Friday. In trading on Friday, information technology shares fell by 0.7%. Top Headline Producer prices in the U.S. increased 0.3% month-over-month in July, recording the biggest rise since January, following a revised flat reading for June. However, analysts were expecting a 0.2% incre
Gainers Amyris, Inc. (NASDAQ:AMRS) shares surged 45.4% to $0.0958 in pre-market trading. Amyris shares dipped over 80% on Thursday after the company announced it filed for Chapter 11 bankruptcy. Semler Scientific, Inc. (NASDAQ:SMLR) rose 40% to $32.85 in pre-market trading after the company reported better-than-expected second-quarter financial results. Eton Pharmaceuticals, Inc. (NASDAQ:ETON) shares gained 25.3% to $3.26 in pre-market trading after posting upbeat second-quarter results. WeWork Inc. (NYSE:WE) shares rose 22.1% to $0.2257 in pre-market trading after jumping 43% on Thursday. The stock has been volatile after the company recently said there was substantial doubt over it
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 150 points on Thursday. The Dow traded up 0.44% to 35,277.94 while the NASDAQ rose 0.29% to 13,761.56. The S&P 500, also rose, gaining, 0.28% to 4,480.22. Check This Out: Disney, Alibaba And 3 Stocks To Watch Heading Into Thursday Leading and Lagging Sectors Communication services shares jumped by 0.4% on Thursday. In trading on Thursday, industrials shares fell by 0.4%. Top Headline Alibaba Group Holding Limited (NYSE:BABA) reported better-than-expected first-quarter financial results. Alibaba reported first-quarter FY23 revenue growth of 14% year-on-year to $32.29 billion, beating the consen
EMERYVILLE, Calif., May 2, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it will issue its financial results for the first quarter ended March 31, 2023, on the afternoon of Tuesday, May 9, 2023, after closing of the financial markets. The company will hold a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time), during which, John Melo, President
Fourth quarter Consumer revenue of $52.8 million increased 64% over the prior year and was another record quarter. Core revenue of $75.8 million grew 17% over the prior yearFull year Consumer revenue of $176.9 million increased 92% and outperformed prestige beauty industry growth of 15%. Core revenue of $269.8 million grew 44% over prior yearUse of cash for operating and investing activities sequentially improved each quarter; Q4 2022 down $102 million versus Q1 2022Actions taken to simplify portfolio, streamline management structure and deliver efficienciesEMERYVILLE, Calif., March 15, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating th
EMERYVILLE, Calif., Feb. 28, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it will issue its financial results for the fourth quarter and full year ended December 31, 2022, on the afternoon of Wednesday, March 15, 2023, after closing of the financial markets. The company will hold a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time), during wh
Sixth consecutive quarter of record consumer revenue – Consumer revenue of $46.6 million increased 98% compared to Q3 2021Record core revenue of $71.1 million grew 49% compared to the prior year quarter"Fit to Win" revenue, cost and cash actions deliver $10 million in Q3$180 million of new funding closed - strategic transaction on track to self-fund growthEMERYVILLE, Calif., Nov. 8, 2022 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced financial results for the third quarter ended September 30, 202
EMERYVILLE, Calif., Nov. 1, 2022 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-MarketTM technology platform and clean beauty consumer brands, today announced that it will issue its financial results for the third quarter ended September 30, 2022, on the afternoon of Tuesday, November 8, 2022, after closing of the financial markets. The company will hold a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time), during which, John Melo
Record consumer revenue of $43 million increased 108% compared to Q2 2021Ingredients sold out in first half with $15 million backlog to be supplied in H2Cost actions and price increases to deliver $50 million of EBITDA improvements in H2$700 million non-equity funding and earnout provides liquidity to sustained profitabilityEMERYVILLE, Calif., Aug. 9, 2022 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-MarketTM technology platform and clean beauty consumer brands, today announced financial results for the second quarter ended June 30, 2022. "Q2 2022 Core revenue of $65.2 m
EMERYVILLE, Calif., July 28, 2022 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform, today announced that it will issue its financial results for the second quarter ended June 30, 2022, on the morning of Tuesday, August 9, 2022, prior to the opening of the financial markets. The company will hold a conference call and webcast at 6:00 a.m. Pacific Time (9:00 a.m. Eastern Time), during which, John Melo, President and Chief Executive Of
Record consumer revenue of $34.6 million increased 121% compared to Q1 2021Barra Bonita commissioning on track to commence ingredients production in Q2EMERYVILLE, Calif., May 10, 2022 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-MarketTM technology platform, today announced financial results for the first quarter ended March 31, 2022. "We continued to advance our growth roadmap, delivering 75% core revenue growth and growing consumer revenue by 121% versus the prior year quarter to a new record of $35 million. Technology access revenue grew 33% year-over-year to $23 mill
EMERYVILLE, Calif., May 3, 2022 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform, today announced that it will issue its financial results for the first quarter ended March 31, 2022, on the morning of Tuesday, May 10, 2022, prior to the opening of the financial markets. The company will hold a conference call and webcast at 6:00 a.m. Pacific Time (9:00 a.m. Eastern Time), during which, John Melo, President and Chief Executive Officer, and Han Kieftenbeld, Chief Financial Officer, will discuss Amyris' financial results and provide an update on the
EMERYVILLE, Calif., March 1, 2022 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-MarketTM technology platform, today announced financial results for its fourth quarter and full year ended December 31, 2021. "Accelerating growth of our consumer brands resulted in record levels for our consumer and core revenue," said John Melo, President and Chief Executive Officer. "Biossance and Pipette, together with better than expected performance of our recently launche